Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04881617 · ClinicalTrials.gov registry record · NA
Treatment for Speech and Language in Primary Progressive Aphasia
A NA study of Aphasia and Primary Progressive Aphasia, sponsored by University of Texas at Austin.
- Active
- Registry status
- NA
- Development phase
- 60
- Enrollment target
- 2
- Study locations
NCT04881617 is a NA study of Aphasia and Primary Progressive Aphasia that is active but no longer recruiting, run by University of Texas at Austin. The registered enrollment target is 60 participants, below the 82-participant average among 42 other Aphasia trials with a reported enrollment target (27% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT04881617, a NA study of Aphasia and Primary Progressive Aphasia, is active but no longer recruiting, sponsored by University of Texas at Austin.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
- 2
- Study locations
Study Summary
Primary progressive aphasia (PPA) is a progressive neurological disorder that causes a gradual decline in communication ability as a result of selective neurodegeneration of speech and language networks in the brain. PPA is a devastating condition affecting adults as young as their 40's or 50's, depriving them of the ability to communicate and function in society. There has been significant progress in discovering the neurobiological mechanisms that underlie PPA and in identifying its clinical phenotypes. With these advances, we are poised to investigate behavioral treatments that are grounded in modern cognitive and neuroanatomical concepts. Research documenting the efficacy of speech-language treatment for PPA is emerging, but limited. Systematic research is needed to establish best clinical practices in this unique patient population for whom pharmacological treatment remains elusive. The long-term objectives of this project are to provide evidence-based treatment methods addressing the speech and language deficits in PPA and to determine the neural predictors of responsiveness to intervention. The study has three main goals that build on the findings of our previous work: 1) to examine the utility of treatments designed to facilitate significant, generalized and lasting improvement of speech-language function in PPA, 2) to determine whether treatment alters the trajectory of decline in PPA by comparing performance on primary outcome measures in treated versus untreated participants after a one-year interval, and 3) to identify imaging predictors (gray matter, white matter, and functional connectivity measures) of responsiveness to behavioral intervention in individuals with PPA. In order to accomplish these aims, we will enroll 60 individuals with PPA, who will undergo a comprehensive multidisciplinary evaluation and neuroimaging. Subsequently, participants will be enrolled in treatment designed to promote lasting and generalized improvement of communicative fun
Conditions Studied
Interventions
- BEHAVIORAL Video-Implemented Script Training for Aphasia (VISTA)
- BEHAVIORAL Lexical Retrieval Training (LRT)
Study Locations (2)
California
- University of California San Francisco - San Francisco
Texas
- University of Texas - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2017-07-01 |
| Est. Completion | 2025-12-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04881617
The ClinicalTrials.gov registry entry for NCT04881617 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 82-participant average among 42 other Aphasia trials with a reported enrollment target (27% lower). The listed sponsor is University of Texas at Austin, which has 257 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Aphasia appearing as the primary indexed condition, and to 2 interventions - of which Video-Implemented Script Training for Aphasia (VISTA) is the first listed.
NCT04881617 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Texas.
Frequently Asked Questions
What is clinical trial NCT04881617 about?
NCT04881617 is a clinical study titled "Treatment for Speech and Language in Primary Progressive Aphasia". Primary progressive aphasia (PPA) is a progressive neurological disorder that causes a gradual decline in communication ability as a result of selective neurodegeneration of speech and language networks in the brain. PPA is a devastating condition affecting adults as young as their 40's or 50's, dep...
What is the current status of trial NCT04881617?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2017-07-01. Estimated completion is 2025-12-30.
What conditions does trial NCT04881617 study?
This clinical trial studies the following conditions: Aphasia, Primary Progressive Aphasia, Logopenic Progressive Aphasia, Semantic Dementia, Nonfluent Aphasia, Progressive.
What interventions are being tested in trial NCT04881617?
The interventions under investigation include: Video-Implemented Script Training for Aphasia (VISTA) (BEHAVIORAL), Lexical Retrieval Training (LRT) (BEHAVIORAL).
Who is sponsoring clinical trial NCT04881617?
This trial is sponsored by University of Texas at Austin, which has 257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04881617 being conducted?
This trial has 2 study locations across California, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Aphasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Transcranial Direct Current Stimulation (tDCS) With Verb Network Strengthening Treatment (VNeST) in Chronic Aphasia
RECRUITING · NA
-
Transcranial Alternating Current Stimulation (tACS) in Aphasia
RECRUITING · NA
-
tACS to Enhance Language Abilities
RECRUITING · NA
-
Treatment Outcomes With tDCS in Post-Stroke Aphasia
RECRUITING · NA
-
Telerehabilitation for Aphasia (TERRA)
RECRUITING · NA
-
Combined Exercise and Targeted Therapy for Post-Stroke Reading Deficits
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.